Daiken Biomedical Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 22, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Capitalization	15,269	14,540	10,860	-	-
Market Cap Growth	44.18%	33.88%	-	-	-
Enterprise Value	13,151	9,496	9,874	-	-
Last Close Price	18.85	17.95	17.34	-	-
PE Ratio	37.23	43.03	101.90	-	-
PS Ratio	8.06	7.67	7.97	-	-
PB Ratio	2.81	2.67	8.31	-	-
P/TBV Ratio	2.81	2.67	8.33	-	-
P/FCF Ratio	56.09	53.42	215.06	-	-
P/OCF Ratio	56.01	53.34	209.86	-	-
EV/Sales Ratio	6.94	5.01	7.25	-	-
EV/EBITDA Ratio	44.55	32.17	64.48	-	-
EV/EBIT Ratio	45.63	32.95	66.31	-	-
EV/FCF Ratio	48.31	34.89	195.53	-	-
Debt / Equity Ratio	0.02	0.02	0.00	1.12	0.60
Debt / EBITDA Ratio	0.40	0.40	0.01	1.35	1.21
Debt / FCF Ratio	0.44	0.44	0.05	2.63	3.27
Net Debt / Equity Ratio	-0.39	-0.39	-0.87	-0.04	-0.47
Net Debt / EBITDA Ratio	-7.17	-7.17	-7.43	-0.05	-0.96
Net Debt / FCF Ratio	-7.78	-7.78	-22.52	-0.10	-2.59
Asset Turnover	0.51	0.51	1.19	1.87	-
Inventory Turnover	2.08	2.08	1.99	1.71	-
Quick Ratio	5.33	5.33	5.36	0.80	1.23
Current Ratio	13.12	13.12	6.56	1.64	2.17
Return on Equity (ROE)	10.01%	10.01%	13.71%	67.55%	-
Return on Assets (ROA)	4.83%	4.83%	8.15%	20.01%	-
Return on Invested Capital (ROIC)	12.85%	13.35%	55.95%	94.00%	77.31%
Return on Capital Employed (ROCE)	5.30%	5.30%	11.40%	68.80%	38.90%
Earnings Yield	2.21%	2.32%	0.98%	-	-
FCF Yield	1.78%	1.87%	0.46%	-	-
Dividend Yield	3.61%	3.89%	2.33%	-	-
Payout Ratio	174.40%	174.40%	2.89%	87.59%	-
Buyback Yield / Dilution	-52.12%	-52.12%	-95.20%	-44.34%	-
Total Shareholder Return	-48.51%	-48.23%	-92.87%	-44.34%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.